Search for content, post, videos

First patient dosed in Affibody and Inmagene trial

Fredrik Frejd

The two companies have announced dosing of the first patient in the global ASPIRE Phase 2 trial evaluating izokibep (IMG-020 or ABY-035) for the treatment of Ankylosing Spondylitis (AS).

ASPIRE

ASPIRE is a global Phase 2, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety and tolerability of izokibep for the treatment of patients with active ankylosing spondylitis (NCT04795141). Inmagene is responsible for all key development activities for the ASPIRE trial, including protocol design, study implementation and oversight. Inmagene has received IND approval/clearance in the US, Mainland China, South Korea, and Taiwan for the ASPIRE trial.

“The ASPIRE study is an important trial to investigate the efficacy of izokibep for AS patients, leveraging the strong safety data from our prior studies,” says Fredrik Frejd, CSO of Affibody. “We expect that both Affibody and Inmagene will be able to use the information from this study to advance the program in additional IL-17 driven indications.”

Photo of Fredrik Frejd: Affibody